Clinical trials: Mycobacterium Abscessus Infection
Pulmonary Disease Due to Mycobacteria (Diagnosis)
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Mycobacterium abscessus (MABS) is a group of rapid-growing, multi-drug resistant non-tuberculous mycobacteria (NTM) causing infections in humans.
- Trial name
- FORMaT (NCT04310930)
- Testing
- Amikacin, Tigecycline, Imipenem
- Where
- 50 sites in Australia, Denmark and 5 more
- Volunteers
- 300 people
- Sponsor
- The University of Queensland
Mycobacterium Abscessus Infection
Inhaled Nitric Oxide for Patients With MABSC
A Prospective, Open labeled, multi-Center, Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently via Inhalation to Subjects with NTM (specifically MABSC) Nitric Oxide (NO) has been shown to play…
- Trial name
- NCT03208764
- Testing
- Nitric Oxide
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Beyond Air Inc.
Mycobacterium Infections
Study of Mycobacterial Infections
This study will examine the symptoms, course of disease and treatment of non-tuberculous mycobacterial (NTM) infections, as well as the genetics involved in these infections.
- Trial name
- NCT00018044
- Testing
- Clofazimine
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with…
- Trial name
- NCT07228702
- Testing
- Mycobacteriophage Muddy_HRMN0052, Amikacin Injection, Clofazimine
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Vancouver Coastal Health
Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical
Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease
The proposed study will assess the efficacy, safety and tolerability of once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance…
- Trial name
- NCT03038178
- Testing
- LAI plus multi-drug regimen
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Kevin Winthrop
Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection
Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to…
- Conditions
- Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections, Non-Tuberculous Mycobacteria Pulmonary Disease
- Trial name
- FORMaT-EVOLVE (NCT07485010)
- Testing
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin
- Volunteers
- 300 people
- Sponsor
- The University of Queensland
Cystic Fibrosis (CF), Mucoviscidosis
Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households
This multicenter, non-interventional case-control study investigates whether household environmental reservoirs, particularly water systems, are associated with non-tuberculous mycobacterial (NTM) infections in people with cystic…
- Conditions
- Cystic Fibrosis (CF), Mucoviscidosis, Non-Tuberculous Mycobacteria, Mycobacterium Abscessus Infection
- Trial name
- NTMecoCF (NCT07369414)
- Testing
- Multi-modal NTM diagnostic including PCR, WGS, culture
- Where
- 2 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Research Center Borstel
Mycobacterium Abscessus Lung Disease, Rapidly Growing Mycobacterial Lung Disease
Tigecycline for Treatment of Rapidly Growing Mycobacteria
To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).
- Trial name
- NCT00600600
- Testing
- Tigecycline
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- The University of Texas Health Science Center at Tyler